TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7882730
Drug: PHB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHB vaccine (20 micrograms per dose)
Study: 20478681
Drug: Supervised Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised Exercise Therapy (SET)
Study: 30025713
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shockwave therapy given over 2 weeks
Study: 24806159
Drug: Letermovir 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 60 mg per day
Study: 10604643
Drug: Fosfomycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin treatment within the first two days of illness
Study: 10604643
Drug: Fosfomycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin treatment on the second day of illness
Study: 10604643
Drug: Fosfomycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin treatment on and after the third day of illness
Study: 10604643
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial agents
Study: 6764935
Drug: Tryptophan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (3 grams daily)
Study: 26076313
Drug: Assist (talk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assist (talk about quitting or recommend stop‐smoking medications or recommend counseling)
Study: 21890583
Drug: Alcohol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.7 g/kg males; 0.63 g/kg females)
Study: 15214221
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of implants with full-arch prostheses after 9 to 18 days
Study: 15214221
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of implants with full-arch prostheses after 2.5 to 5.1 months
Study: 7702447
Drug: Focal interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal interpersonal therapy
Study: 22133036
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) therapy
Study: 32776
Drug: Lorazepam (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3.2 mg twice daily)
Study: 12932243
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil topical solution
Study: 8865946
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g as single shot prophylaxis before hemodilution (group A)
Study: 8865946
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g as single shot prophylaxis after hemodilution (group B)
Study: 1909700
Drug: Mesna (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesna (20% of ifosfamide dose, intravenously, three times daily for 5 days)
Study: 6090258
Drug: Adrenergic blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic blockers (phentolamine and propranolol)
Study: 6090258
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of opioid and adrenergic blockers
Study: 30878146
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (clinical trial participants)
Study: 8472520
Drug: ST‐679 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST‐679 (1200 mg, single oral dose)
Study: 20817859
Drug: SDAP (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDAP (10% spray-dried animal plasma)
Study: 20817859
Drug: auSDAP (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: auSDAP (10% autoclaved spray-dried animal plasma)
Study: 19387397
Drug: CM (5
Normalized name: fibrinogen/thrombin(human der) 9.5 cm X 4.8 cm (5.5 mg-2 unit/cm2) TOPICAL ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM (5 g of creatine)
Study: 19387397
Drug: PEG1.25 (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG1.25 (1.25 g of creatine)
Study: 11474311
Drug: pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 20 mg daily
Study: 11474311
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg daily
Study: 7920000
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment for 4 to 20 months (mean 10.6 months)
Study: 3414572
Drug: [1‐13C]palmitic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: [1‐13C]palmitic acid (9‐13.5 mg/kg body wt)
Study: 3414572
Drug: [16‐13C]palmitic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: [16‐13C]palmitic acid (9‐13.5 mg/kg body wt)
Study: 21690318
Drug: Tobacco smoking
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco smoking with nicotine yield (0.05, 0.6, or 0.9 mg)
Study: 10929922
Drug: Fexofenadine 60
Normalized name: fexofenadine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 60 mg twice daily
Study: 18096307
Drug: Photodynamic diagnosis
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic diagnosis (PDD) with hexaminolevulinate (Hexvix) solution
Study: 12873920
Drug: IV test
Normalized name: home HIV test kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV test dose (0.1 mL/kg) consisting of 1% lidocaine with 1:200,000 epinephrine (epinephrine 0.5 microg/kg)
Study: 10723498
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily didanosine plus twice daily stavudine (group B)
Study: 10723498
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily didanosine plus twice daily stavudine (group A)
Study: 8528821
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified treatment)
Study: 1958432
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment with good medication compliance (≥90% capsule consumption)
Study: 1958432
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment with good medication compliance (≥90% positive gemfibrozil analyses)
Study: 1958432
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment with good medication compliance (good compliance according to both digoxin marker measurements)
Study: 1958432
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment with poor medication compliance (<50% capsule consumption)
Study: 1958432
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment with poor medication compliance (<50% positive gemfibrozil analyses)
Study: 1958432
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment with poor medication compliance (poor results in both digoxin marker measurements)
Study: 6890361
Drug: Acebutolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 300 mg
Study: 3910303
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg
Study: 6890361
Drug: Acebutolol (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (any dose)
Study: 30921503
Drug: OLZ/SAM (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ/SAM (10 mg OLZ/10 mg SAM) in fed conditions
Study: 30921503
Drug: OLZ/SAM (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ/SAM (10 mg OLZ/10 mg SAM) in fasted conditions
Study: 23851908
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) treatment
Study: 15001247
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (with rectangular fields) to a dose of 66 Gy
Study: 15001247
Drug: Three-dimensional conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional conformal radiotherapy to a dose of 66 Gy
Study: 15001247
Drug: Dose levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels between 25 Gy and 60 Gy
Study: 28714866
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents
Study: 25239483
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated SA 14-14-2 JE vaccine manufactured in a new GMP facility
Study: 12950711
Drug: Trazodone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (mean dose = 105 +/- 57 mg at bedtime)
Study: 10786962
Drug: Neutralizing antibody
Normalized name: Neutralizing antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibody to tumor necrosis factor
Study: 10786962
Drug: Recombinant interleukin
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interleukin 1 receptor antagonist
Study: 9561598
Drug: DTP-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-HB vaccine administered at 2, 4, and 6 months
Study: 9561598
Drug: DTP-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-HB vaccine
Study: 4036270
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml intradermally (ID)
Study: 4036270
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml subcutaneously (SC)
Study: 4036270
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml SC
Study: 28111208
Drug: Pre-operative intramuscular
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intramuscular testosterone enanthate (2 mg/kg) administered in Group 2 (subdivided into Group 2A and Group 2B based on timing of surgery)
Study: 25872501
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of the management algorithm for tuberculosis diagnosis and treatment in intervention clinics.
Study: 20031704
Drug: IVUS-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVUS-directed therapy
Study: 2520847
Drug: Misoprostol 100
Normalized name: MISOPROSTOL 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 100 mcg
Study: 31401795
Drug: SNF472 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNF472 (intravenous formulation of myo-inositol hexaphosphate) administered 3 times per week for 12 weeks
Study: 27893019
Drug: Blunt-needle injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blunt-needle injection (lidocaine, 2%; 27-gauge needle)
Study: 27893019
Drug: Sharp-needle injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sharp-needle injection
Study: 23822690
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (50 mg/kg body wt)
Study: 9509896
Drug: Anti-platelet treatment
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-platelet treatment with dipyridamole
Study: 8311489
Drug: CGS16949A 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS16949A 8 mg single dose
Study: 8311489
Drug: CGS16949A 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS16949A 8 mg/day (multiple administration)
Study: 8311489
Drug: CGS16949A 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS16949A 16 mg/day (multiple administration)
Study: 8311489
Drug: CGS16949A (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS16949A (multiple administration)
Study: 30001987
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg/day
Study: 26276968
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg weekly for 12 weeks
Study: 21968445
Drug: Quadrovax(®) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrovax(®) vaccine
Study: 21968445
Drug: TETRAct-Hib(®) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETRAct-Hib(®) vaccine
Study: 19917097
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (techniques chosen by the surgeon)
Study: 19917097
Drug: Standard non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard non-surgical treatment
Study: 12615677
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg
Study: 15492322
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg
Study: 9526175
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution containing 2g carnitine (Group B)
Study: 9526175
Drug: 5% glucose‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose‐enriched solution (Group A)
Study: 2202547
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol and 20 mg nifedipine (1 capsule once daily)
Study: 2202547
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol and 20 mg nifedipine (2 capsules once daily)
Study: 2202547
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol and 20 mg nifedipine (1 capsule or 2 capsules once daily)
Study: 31532044
Drug: Moringa stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa stem meal (MSM) at 100 g/kg
Study: 31532044
Drug: Moringa stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa stem meal (MSM) at 60 g/kg or less
Study: 31532044
Drug: Moringa stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa stem meal (MSM) at 0 g/kg (control)
Study: 25408262
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of erlotinib 150 mg
Study: 25408262
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of erlotinib 150 mg
Study: 16691030
Drug: 1% pimecrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pimecrolimus cream (Elidel) applied twice daily for 2 weeks
Study: 7934970
Drug: Acipimox slow
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox slow release (ACX‐SR, 500 mg)
Study: 29084372
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg of HGF per vocal fold
Study: 29084372
Drug: 3 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg of HGF per vocal fold
Study: 29084372
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg of HGF per vocal fold
Study: 23930950
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (10⁹ colony-forming units twice daily; n=20)
Study: 14648521
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose and non‐nutritive sucking (NNS)
Study: 10820932
Drug: Accelerated streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated streptokinase infusion over 15 minutes (group 1, n = 24)
Study: 10820932
Drug: Conventional streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional streptokinase infusion over one hour (group 2, n = 23)
Study: 8648213
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of Ty800 (10^7, 10^8, 10^9, or 10^10 cfu)
Study: 28077825
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of essential oil
Study: 29499722
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and regular clinical assessment
Study: 26806141
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment only (Control)
Study: 7836217
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg)
Study: 25075
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg)
Study: 1127891
Drug: Different treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatment conditions
Study: 21613558
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D concentrations (≥52 nmol/L)
Study: 19220313
Drug: Memantine 20-40
Normalized name: memantine hydrochloride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20-40 mg/day
Study: 22434327
Drug: Good Behavior
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good Behavior Game (GBG) intervention, with training and weekly on-site support from coaches.
Study: 20362342
Drug: Sequential immunizations
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential immunizations (control group)
Study: 15896512
Drug: Oligofructose (OF)
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (OF) 6 g daily for 15 days
Study: 10065691
Drug: Domperidone (a
Normalized name: Domperidone (as domperidone maleate) 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (a selective dopamine D2‐receptor antagonist)
Study: 1959848
Drug: Sclerotherapy (paravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy (paravenous polidocanol [10 mg/ml] every 1 to 2 weeks until eradication)
Study: 1959848
Drug: Propranolol (slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (slow-release preparation in one daily dose adjusted to provide about 25% heart rate reduction)
Study: 25312529
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) - conventional electrosurgical pencil
Study: 19042026
Drug: Risperidone 0.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5-4 mg/day
Study: 15789141
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (COL; 20 g daily)
Study: 8926739
Drug: Cannabinoid immunoassays
Normalized name: Cannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid immunoassays with 50‐ng/mL cutoff
Study: 8926739
Drug: Cannabinoid immunoassays
Normalized name: Cannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid immunoassays with 20‐ng/mL cutoff
Study: 8926739
Drug: Commercial cannabinoid
Normalized name: Cannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial cannabinoid immunoassay with a 50‐ng/mL cutoff
Study: 19057518
Drug: Coadministered amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministered amlodipine 5 mg and atorvastatin 10 mg
Study: 17324005
Drug: Cinacalcet 30
Normalized name: cinacalcet 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 30 mg twice daily
Study: 11870141
Drug: Combined data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined data from IvIg treatment
Study: 11870141
Drug: Combined data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined data from placebo treatment
Study: 7856293
Drug: 24-valent Klebsiella
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-valent Klebsiella capsular polysaccharide vaccine and eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously
Study: 7856293
Drug: 24-valent Klebsiella
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-valent Klebsiella capsular polysaccharide vaccine and eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered 14 days apart
Study: 24135593
Drug: 750 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 µg of AFB1/kg diet (750 ppb of AFB1)
Study: 24135593
Drug: 75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 µg of AFB1/kg diet (75 ppb of AFB1)
Study: 21458097
Drug: Liraglutide (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (once-daily injection for 16 weeks)
Study: 21458097
Drug: T2DM (pre-treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2DM (pre-treatment)
Study: 8281852
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg
Study: 9665421
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg/day)
Study: 7655766
Drug: Pranidipine (1‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranidipine (1‐2 mg) once daily for 1‐2 weeks
Study: 10210991
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment
Study: 1139128
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of subcutaneous sodium heparin
Study: 27230862
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) + Usual Care (UC) for 16 weeks